Global approved new drugs in 2023:retrospect and prospectYANG Zhen-zheng, SU Xiao-yu, SUN You-song, CHEN Qian, WANG Yun1633-1640
An empirical study on the influence factors of cooperative relationship in entrusted production by marketing authorization holdersWANG Xue-ya, PAN Xiao-ying, MAO Ning-ying1641-1646
Analysis of common problems in chemical manufacturing and control dossiers and research of supplemental applications for post-approval chemical drugsWU Xiao-fei, LIU Dan-xing, ZHANG Xin, WANG Hong-liang, BAI Yu1647-1652
Compliance information management of drug registration and research and development entities under the drug marketing authorization holder systemHE Hui, LIU Yi-di, BAN Hao, ZHOU Gang1653-1658
Progress and challenges in the implementation of 3Rs quality control approaches in WHO guidelines on biologicalsHE Qing, TAN De-jiang, MA Xiao, ZHENG Yi-yang, LIU Si-han, ZHANG Yu, WANG Jun-zhi1659-1664
Strategy and progress in research on multi-target drugsLI Zheng, PENG Can, LI Xi-chen, DONG Guo-sheng, HAN Yu-fei, ZHANG Tao, TANG Li-jun1665-1675
Progress in acute treatment of migraine with calcitonin gene-related peptide receptor antagonistsWANG Zhuang, WANG Tian-xiao, ZHANG Rui, XU Yu-ming1676-1680
Combination therapy of methotrexate and iguratimod for female patients with moderate to severe active rheumatoid arthritis and its impact on ovarian functionWANG Ying-fang, CHEN Fang, WANG Liu-qing, DU Hong-wei, XU Chen, TANG Fei1681-1686
Analysis of the concerns and problems found by the U.S.FDA bioresearch monitoring program in clinical investigator inspectionJIANG Min, ZHAO Shu-hua, LIU Xiao-hong, FU Zhi-ying, YUAN Yan-nan1687-1692
Common problems and improvement strategies of quality management in investigators-initiated clinical trialsHUANG Ying-shuo, ZUO Xu, LI Yue, XING Li-han, GUO Shui-long, WANG Zhen-chang, ZHANG Shu-tian1693-1698